Mostrar el registro sencillo del ítem

dc.contributor.authorGutiérrez Abejón, Eduardo
dc.contributor.authorHerrera Gómez, Francisco Magno
dc.contributor.authorCriado Espegel, Paloma
dc.contributor.authorÁlvarez González, Francisco Javier 
dc.date.accessioned2021-03-16T10:46:15Z
dc.date.available2021-03-16T10:46:15Z
dc.date.issued2017
dc.identifier.citationBMJ Open, 2017, vol. 7. 10 p.es
dc.identifier.issn2044-6055es
dc.identifier.urihttp://uvadoc.uva.es/handle/10324/45766
dc.descriptionProducción Científicaes
dc.description.abstractObjective: To assess the use of driving-impairing medicines (DIM) in the general population with special reference to length of use and concomitant use. Design: Population-based registry study. Setting: The year 2015 granted medicines consumption data recorded in the Castile and León (Spain) medicine dispensation registry was consulted. Participants: Medicines and DIM consumers from a Spanish population (Castile and León: 2.4 million inhabitants). Exposure Medicines and DIM consumption. Patterns of use by age and gender based on the length of use (acute: 1–7 days, subacute: 8–29 days and chronic use: ≥30 days) were of interest. Estimations regarding the distribution of licensed drivers by age and gender were employed to determine the patterns of use of DIM. Results: DIM were consumed by 34.4% (95% CI 34.3% to 34.5%) of the general population in 2015, more commonly with regularity (chronic use: 22.5% vs acute use: 5.3%) and more frequently by the elderly. On average, 2.3 DIM per person were dispensed, particularly to chronic users (2.8 DIM per person). Age and gender distribution differences were observed between the Castile and León medicine dispensation registry data and the drivers’ license census data. Of all DIM dispensed, 83.8% were in the Anatomical Therapeutic Chemical code group nervous system medicines (N), which were prescribed to 29.2% of the population. Conclusions: The use of DIM was frequent in the general population. Chronic use was common, but acute and subacute use should also be considered. This finding highlights the need to make patients, health professionals, health providers, medicine regulatory agencies and policy-makers at large aware of the role DIM play in traffic safety.es
dc.format.mimetypeapplication/pdfes
dc.language.isoenges
dc.publisherBMJ Journalses
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subject.classificationDrivinges
dc.subject.classificationConducciónes
dc.subject.classificationDrug utilizationes
dc.subject.classificationUso de medicamentoses
dc.titleUse of driving-impairing medicines by a Spanish population: a population-based registry studyes
dc.typeinfo:eu-repo/semantics/articlees
dc.rights.holder© 2017 BMJ Journalses
dc.identifier.doi10.1136/bmjopen-2017-017618es
dc.relation.publisherversionhttps://bmjopen.bmj.com/content/7/11/e017618es
dc.peerreviewedSIes
dc.description.projectInstituto de Salud Carlos III - Red de Trastornos Adictivos (grant RD16/0017/0006)es
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersiones


Ficheros en el ítem

Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem